Editorial: an argument for low‐dose thiopurine allopurinol combination use as first‐line therapy in inflammatory bowel disease

Linked Content This article is linked to Friedman et al and Friedman and Sparrow papers. To view these articles visit https://doi.org/10.1111/apt.14571 and https://doi.org/10.1111/apt.14798 .